Oxford Biomedica plc

OTCPK:OXBD.F Stock Report

Market Cap: US$534.4m

Oxford Biomedica Valuation

Is OXBD.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of OXBD.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$18.07
Fair Value
70.8% undervalued intrinsic discount
8
Number of Analysts

Below Fair Value: OXBD.F ($5.27) is trading below our estimate of fair value ($18.07)

Significantly Below Fair Value: OXBD.F is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for OXBD.F?

Key metric: As OXBD.F is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for OXBD.F. This is calculated by dividing OXBD.F's market cap by their current revenue.
What is OXBD.F's PS Ratio?
PS Ratio4.4x
SalesUK£97.28m
Market CapUK£432.23m

Price to Sales Ratio vs Peers

How does OXBD.F's PS Ratio compare to its peers?

The above table shows the PS ratio for OXBD.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average5.6x
EBS Emergent BioSolutions
0.5x6.1%US$557.0m
PRTA Prothena
5.7x36.8%US$761.4m
AKBA Akebia Therapeutics
2.3x28.9%US$405.8m
CVAC CureVac
14x-5.1%US$1.0b
OXBD.F Oxford Biomedica
4.4x21.2%US$432.2m

Price-To-Sales vs Peers: OXBD.F is good value based on its Price-To-Sales Ratio (4.4x) compared to the peer average (5.6x).

Price to Sales Ratio vs Industry

How does OXBD.F's PS Ratio compare vs other companies in the US Biotechs Industry?

134 CompaniesPrice / SalesEstimated GrowthMarket Cap
GILD Gilead Sciences
3.9x2.8%US$112.95b
BIIB Biogen
2.3x1.3%US$22.32b
MRNA Moderna
3.3x13.5%US$18.29b
INCY Incyte
3.5x5.6%US$14.10b
OXBD.F 4.4xIndustry Avg. 10.7xNo. of Companies134PS01632486480+
134 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: OXBD.F is good value based on its Price-To-Sales Ratio (4.4x) compared to the US Biotechs industry average (10.7x).

Price to Sales Ratio vs Fair Ratio

What is OXBD.F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

OXBD.F PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4.4x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate OXBD.F's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst OXBD.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$5.27
US$6.76
+28.2%
19.8%US$9.38US$4.82n/a8
Jan ’26US$5.40
US$6.76
+25.2%
19.8%US$9.38US$4.82n/a8
Dec ’25n/a
US$6.73
0%
20.5%US$9.43US$4.84n/a8
Nov ’25US$5.65
US$6.71
+18.7%
23.3%US$9.60US$4.93n/a7
Oct ’25US$5.02
US$6.63
+32.0%
28.4%US$9.88US$4.07n/a7
Sep ’25US$4.43
US$6.04
+36.2%
34.7%US$9.43US$3.19n/a7
Aug ’25US$4.89
US$5.68
+16.1%
36.8%US$9.36US$3.16n/a8
Jul ’25US$3.72
US$5.68
+52.6%
36.8%US$9.36US$3.16n/a8
Jun ’25n/a
US$5.73
0%
36.8%US$9.45US$3.19n/a8
May ’25US$2.91
US$5.25
+80.4%
45.6%US$9.30US$2.26n/a8
Apr ’25US$2.43
US$5.28
+117.2%
46.2%US$9.40US$2.29n/a8
Mar ’25US$2.18
US$5.33
+144.6%
41.7%US$9.06US$2.64n/a8
Feb ’25US$2.37
US$5.33
+125.1%
41.7%US$9.06US$2.64n/a8
Jan ’25US$2.69
US$5.33
+98.2%
41.7%US$9.06US$2.64US$5.408
Dec ’24US$2.24
US$5.49
+145.1%
40.0%US$9.14US$3.36n/a7
Nov ’24US$2.65
US$8.66
+226.9%
93.4%US$29.14US$3.22US$5.658
Oct ’24US$3.57
US$9.11
+155.7%
89.9%US$29.17US$3.22US$5.028
Sep ’24US$4.22
US$11.75
+178.4%
62.9%US$30.58US$4.65US$4.439
Aug ’24n/a
US$11.83
0%
61.6%US$30.52US$4.64US$4.899
Jul ’24US$5.38
US$11.72
+117.9%
61.6%US$30.27US$4.60US$3.729
Jun ’24US$5.47
US$13.46
+146.4%
51.9%US$29.67US$6.49n/a7
May ’24n/a
US$14.42
0%
52.2%US$30.16US$6.60US$2.916
Apr ’24US$5.24
US$12.72
+143.1%
57.5%US$28.68US$4.30US$2.437
Mar ’24US$6.25
US$12.72
+103.6%
57.5%US$28.68US$4.30US$2.187
Feb ’24US$5.10
US$12.72
+149.5%
57.5%US$28.68US$4.30US$2.377
Jan ’24US$5.22
US$12.72
+143.8%
57.5%US$28.68US$4.30US$2.697
Analyst Price Target
Consensus Narrative from 8 Analysts
US$6.89
Fair Value
23.5% undervalued intrinsic discount
8
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/09 11:25
End of Day Share Price 2025/01/07 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Oxford Biomedica plc is covered by 16 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Rick BienkowskiCantor Fitzgerald & Co.
Susie JanaEdison Investment Research
Jens LindqvistInvestec Bank plc (UK)